In this economic situation there is a clear limitation about the use of new antithrombotic drugs. However, in my opinion there is a marked underuse of NOACs. Several reasons are underlying this situation. What is your opinion?
But, we have several concern about safety (lack of antidot and variability of management) and analytical control (lack of specific assays) without practical answer